Asston Pharmaceuticals Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Asston Pharmaceu

CMP

87.80

-1.19 (-1.34%)

  • DRHP
₹123

Offer Price

₹ 27.56 Cr

Issue Size

₹ 2,46,000

Min Investment

2,000

Lot size

Time Line

  • 09
    Jul 2025
    Open
  • 11
    Jul 2025
    Close
  • 14
    Jul 2025
    Finalisation of Basis of Allotment
  • 15
    Jul 2025
    Initiation of Refunds
  • 15
    Jul 2025
    Transfer of Shares to Demat Account
  • 16
    Jul 2025
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Expanding our footprint.

  • Expanding our product offerings.

  • Increase our warehouse capabilities.

  • Increase the numbers of contract manufacturers.

  • Investment and upgradation in Information Technology (IT) and other digital initiatives.

Products & Services

  • The Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets.

Strengths

  • Formulation Expertise.

  • Experienced Promoters.

  • Wide range of Products.

  • Strategic Location.

  • Skilled Workforce.

Risks

  • The Company operates in pharmaceutical sector, which is extensively regulated, any failures on its part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financial condition.

  • The company operate its own manufacturing facility for pharmaceutical products; however for certain products other than tablets, the company relies on third-party manufacturers to procure the pharmaceutical products.

  • The company depends on the success of its relationships with the company customers. The company derives a significant part of its revenue from its major customers and the company does not have long-term contracts with these customers other than contracts with 2 customers for one year. If one or more of such customers choose not to source their requirements from it, the company business, financial condition and results of operations may be adversely affected.

  • The loss of contract manufacturing tie-ups and the low entry barrier for contract manufacturing can affect production, order intake, revenue, cash flow, and profitability. The absence of exclusive agreements increases the risk of delays or disruptions in order execution, further impacting business operations.

  • The company has substantial working capital expenditure and may requires additional financing to meet those requirements and have risk of receivables, which could have an adverse effect on its results of operations and financial condition.

Company Promoters

Promoters Holding

Issue For IPO
18.10%
Pre Holding

68.76%

Post Holding

50.66%

Top Promoters Holding

Financials

All values in Cr

Mar-2022 Mar-2023 Mar-2024 3-Yr trend
Revenue 9.60 (-) 6.54 (-31.90%) 15.59 (138.40%)
Gross Profit 0.17 (-) 1.45 (752.90%) 1.87 (29.00%)
Net Income 0.11 (-) 1.06 (863.60%) 1.36 (28.30%)
Assets 4.29 (-) 7.30 (70.20%) 13.37 (83.20%)
Liabilities 3.36 (-) 5.31 (58.00%) 6.98 (31.50%)

Book Running Managers

  • Sobhagya Capital Options Pvt. Ltd.

Registrar & Transfer Agent

Maashitla Securities Pvt Ltd

451 Krishna Apra Bus,
Netaji Subhash Place,
Pitampura - New Delhi-110034
Phone : 011-45121795 Fax: 01145121795

Company Contact Information

4th Flr Office No.A-431 Balaji,
Bhavan Plot No.42A Sec-11 CBD,
Mumbai - 400614
Phone : +91 22 4973 1411/+91 22 4973 1419 Email : info@asstonpharmaceuticals.com www.asstonpharmaceuticals.com

Offer Related Information

Initial public issue of up to 22,41,000 equity shares of face value of Rs.10/- each (the "Equity Shares") of Asston Pharmaceuticals Limited ("the Company" or "APL" or "the Issuer") at an issue price of Rs. 123 per equity share for cash, aggregating up to Rs. 27.56 crores ("Public Isue") out of which upto 1,13,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 123 per equity share for cash, aggregating Rs. 1.39 crores will be reserved for subscription by the market maker... More

Asston Pharmaceu FAQ's

The shares of Asston Pharmaceu were first listed on the stock exchanges on June 26, 2024.

The total issue size of the Asston Pharmaceu IPO was 1,10,00,000 shares, amounting to Rs. 132 crore. they

The minimum lot size for Asston Pharmaceu public issue was 125 shares.

The price band of the IPO of Asston Pharmaceu was Rs. 114 to Rs. 120 per equity share.

Asston Pharmaceu IPO is a public issue through which the company raised approximately Rs. 132 crore by issuing around 1.1 crore equity shares to the public. After a successful IPO, the company’s shares are currently listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), where they are freely traded without restrictions.

Bigshare Services Private Limited is the registrar and share transfer agent of Asston Pharmaceu IPO.

Download Our App On: